OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia
Wenyan Liu, Yu Bai, Licheng Zhou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 115974-115974
Closed Access | Times Cited: 6
Wenyan Liu, Yu Bai, Licheng Zhou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 115974-115974
Closed Access | Times Cited: 6
Showing 6 citing articles:
Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins
Melisa Halilovic, Mohamed Abdelsalam, Joanna Zabkiewicz, et al.
Leukemia (2024) Vol. 38, Iss. 12, pp. 2561-2572
Open Access | Times Cited: 5
Melisa Halilovic, Mohamed Abdelsalam, Joanna Zabkiewicz, et al.
Leukemia (2024) Vol. 38, Iss. 12, pp. 2561-2572
Open Access | Times Cited: 5
Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors
Junwei Wang, Quanjin Rong, Lei Ye, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 7197-7223
Closed Access | Times Cited: 4
Junwei Wang, Quanjin Rong, Lei Ye, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 7197-7223
Closed Access | Times Cited: 4
Discovery of FLT3-targeting PROTACs with potent antiproliferative activity against acute myeloid leukemia cells harboring FLT3 mutations
Zhijie Wang, Xun Lu, Canlin Liu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116237-116237
Closed Access | Times Cited: 2
Zhijie Wang, Xun Lu, Canlin Liu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116237-116237
Closed Access | Times Cited: 2
Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia
Lei Ye, Zhenzhen Cui, Yu Sun, et al.
Bioorganic Chemistry (2024) Vol. 149, pp. 107477-107477
Closed Access | Times Cited: 1
Lei Ye, Zhenzhen Cui, Yu Sun, et al.
Bioorganic Chemistry (2024) Vol. 149, pp. 107477-107477
Closed Access | Times Cited: 1
FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives
Heba M. Hesham, Eman M.E. Dokla, Eman Z. Elrazaz, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116717-116717
Closed Access | Times Cited: 1
Heba M. Hesham, Eman M.E. Dokla, Eman Z. Elrazaz, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116717-116717
Closed Access | Times Cited: 1
Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges
Jan Rataj, Lukáš Górecki, Darina Muthná, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 182, pp. 117788-117788
Open Access | Times Cited: 1
Jan Rataj, Lukáš Górecki, Darina Muthná, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 182, pp. 117788-117788
Open Access | Times Cited: 1
